RecruitingPhase 1NCT06040541
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
Sponsor
Revolution Medicines, Inc.
Enrollment
604 participants
Start Date
Sep 7, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
- ECOG performance status 0 or 1
- Adequate organ function
Exclusion Criteria4
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or active brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)
Interventions
DRUGRMC-9805
Oral Tablets
DRUGRMC-6236
Oral Tablets
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06040541
Related Trials
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT072230478 locations
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
NCT051000691 location
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788217 locations